Longboard Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Longboard Pharmaceuticals specializes in providing patients suffering from rare neurological diseases with advanced medicines that have been optimized for both their effectiveness and the way they interact with the body. The company has a range of programs in its development pipeline that have a wide range of potential uses in clinical settings. One such program is the evaluation of LP352, which is a new and improved version of a 5-HT2C agonist. This particular drug is being studied for its potential to treat developmental and epileptic encephalopathies (DEEs). Additionally, Longboard is also examining the effectiveness of two other drugs, LP143 and LP659. LP143 is a type 2 cannabinoid receptor (CB2) agonist that acts primarily in the central nervous system. Lastly, LP659 is a next-generation, highly selective modulator of the S1P receptor, and it, too, primarily affects the central nervous system.
Longboard Pharmaceuticals has raised $23.0M across 2 funding rounds on record, the most recent an undisclosed round announced in Jan 2024.
Longboard Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Jan 2024.
Longboard Pharmaceuticals Funding Rounds
1 of 2 rounds was announced without a disclosed amount and is excluded from the total.
Longboard Pharmaceuticals raised $23.0M in an undisclosed round announced in Feb 2023.
11 months later, an undisclosed round was announced in Jan 2024 with no disclosed amount.
Longboard Pharmaceuticals Founders and Leadership Team
Contact details for the Longboard Pharmaceuticals team: 1 of 1 has an email address on file.
Start 14-day free trial →Longboard Pharmaceuticals Funding Compared to Other Biotechnology Startups
Funded Startups Like Longboard Pharmaceuticals in Biotechnology and San Diego
Companies Similar to Longboard Pharmaceuticals
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Longboard Pharmaceuticals Funding FAQs
What does Longboard Pharmaceuticals do?
Longboard Pharmaceuticals specializes in providing patients suffering from rare neurological diseases with advanced medicines that have been optimized for both their effectiveness and the way they interact with the body. The company has a range of programs in its development pipeline that have a wide range of potential uses in clinical settings. One such program is the evaluation of LP352, which is a new and improved version of a 5-HT2C agonist. This particular drug is being studied for its potential to treat developmental and epileptic encephalopathies (DEEs). Additionally, Longboard is also examining the effectiveness of two other drugs, LP143 and LP659. LP143 is a type 2 cannabinoid receptor (CB2) agonist that acts primarily in the central nervous system. Lastly, LP659 is a next-generation, highly selective modulator of the S1P receptor, and it, too, primarily affects the central nervous system.
How much funding has Longboard Pharmaceuticals raised?
Longboard Pharmaceuticals has raised $23.0M across 2 rounds on record.
When did Longboard Pharmaceuticals last raise funding?
Longboard Pharmaceuticals' most recent funding round on record was announced in Jan 2024. The amount was not disclosed.
Who founded Longboard Pharmaceuticals?
FundedIQ lists Kevin R Lind (Founder) at Longboard Pharmaceuticals.
Where is Longboard Pharmaceuticals headquartered?
Longboard Pharmaceuticals is based in San Diego, California, United States.
How many employees does Longboard Pharmaceuticals have?
Longboard Pharmaceuticals is in the 51-100 employee band.
About FundedIQ's Longboard Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Longboard Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.